Aura Biosciences Q3 2026 Results: Net Loss of $32.1M, Loss Widens
Aura Biosciences reported a significant increase in net loss to $111.4 million for the nine months ended September 30, 2026, driven by rising R&D and G&A expenses. Despite the loss, the company strengthened its balance sheet through a follow-on offering, ending the period with $303.1 million in current assets compared to $149.7 million at the end of 2025.
- Key figure
- Net loss $32.1M